Zinc Antagonizes Homocysteine-Induced Fetal Heart Defects in Rats
Tóm tắt
It has been suggested that zinc may have a protective role against heart defects during fetal development. We investigated the effects of zinc on the development of fetal cardiac malformations induced by homocysteine. Pregnant Sprague–Dawley rats were randomized into one of five groups: control (C), homocysteine (H), homocysteine + zinc (Z), homocysteine + folic acid (F), or homocysteine + zinc + folic acid (ZF) (each n = 8). Homocysteine (8 nmol/day) was administered intraperitoneally in the H, Z, F, and ZF groups on gestation days (GD) 8, 9, and 10. Zinc (30 mg/kg day), folic acid (30 mg/kg day), or both (30 mg/kg day each) were administered intragastrically daily in the Z, F, and ZF groups, respectively, throughout the pregnancy. In each group, two fetuses were removed on GD 13, 15, 17, and 19 and examined for cardiac malformations; maternal copper/zinc-containing-superoxide dismutase (Cu/Zn–SOD) activity and metallothionein type I (MT-1) mRNA expression were measured simultaneously. The prevalence of cardiac malformations was significantly higher in group H than in group C, and significantly lower in group Z than in group H at the studied time points. Cu/Zn–SOD activity and MT-1 mRNA levels were significantly lower in group H than in group C, and significantly higher in group Z than in group H. Our data suggest that zinc antagonizes homocysteine-induced teratogenic effects on the fetal heart, possibly via the inhibition of excessive peroxidation.
Tài liệu tham khảo
Bentham, J., & Bhattacharya, S. (2008). Genetic mechanisms controlling cardiovascular development. Annals of the New York Academy of Sciences, 1123, 10–19.
Tennstedt, C., Chaoui, R., Korner, H., & Dietel, M. (1999). Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: Results of a seven year necropsy study. Heart, 82, 34–39.
Botto, L. D., & Correa, A. (2003). Decreasing the burden of congenital heart anomalies: An epidemiologic evaluation of risk factors and survival. Progress in Pediatric Cardiology, 18, 111–121.
Verkleij-Hagoort, A. C., Verlinde, M., Ursem, N. T., Lindemans, J., Helbing, W. A., Ottenkamp, J., et al. (2006). Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG, 113, 1412–1418.
Beksac, M. S., Balci, S., Guvendag-Guven, E. S., Guven, S., & Ozkutlu, S. (2007). Complex conotruncal cardiac anomalies consecutively in three siblings from a consanguineous family possibly associated with maternal hyperhomocysteinemia. Archives of Gynecology and Obstetrics, 276, 547–549.
van Beynum, I. M., Kouwenberg, M., Kapusta, L., & den Heijer, M. (2006). MTRR 66A>G polymorphism in relation to congenital heart defects. Clinical Chemistry and Laboratory Medicine, 44, 1317–1323.
Taparia, S., van Waes, G. J., Rosenquist, T. H., & Finnell, R. H. (2007). Importance of folate-homocysteine homeostasis during early embryonic development. Clinical Chemistry and Laboratory Medicine, 45, 1717–1727.
Moens, L., Vrints, C. J., Claeys, M. J., Timmermans, J. P., Champion, H. C., & Kass, D. A. (2008). Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. American Journal of Physiology. Heart and Circulatory Physiology, 294, H1971–H1977.
Botto, L. D., Mulinare, J., & Erickson, J. D. (2000). Occurrence of congenital heart defects in relation to maternal multivitamin use. American Journal of Epidemiology, 151, 878–884.
Arbour, L., Rupps, R., MacDonald, S., Forth, M., Yang, J., Nowdluk, M., et al. (2006). Congenital heart defects in Canadian Inuit: Is more folic acid making a difference? Alaska Medicine, 49(Suppl. 2), 163–166.
Formigari, A., Irato, P., & Santon, A. (2007). Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: Biochemical and cytochemical aspects. Comparative Biochemistry and Physiology. Toxicology & Pharmacology, 146, 443–459.
Hobbs, C. A., Malik, S., Zhao, W., James, S. J., Melnyk, S., & Cleves, M. A. (2006). Maternal homocysteine and congenital heart defects. American College of Cardiology Journal, 47, 683–685.
L’abbe, M. R., & Fischer, P. W. (1986). An automated method for the determination of Cu, Zn-superoxide dismutase in plasma and erythrocytes using an ABA-200 discrete analyzer. Clinical Biochemistry, 19, 175–178.
Hobbs, C. A., Cleves, M. A., Melnyk, S., Zhao, W., & James, S. J. (2005). Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. American Journal of Clinical Nutrition, 81, 147–153.
Elmore, C. L., Wu, X., Leclerc, D., Watson, E. D., Bottiglieri, T., Krupenko, N. I., et al. (2007). Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Molecular Genetics and Metabolism, 91, 85–97.
Powell, S. R. (2000). The antioxidant properties of zinc. The Journal of Nutrition, 130(Suppl. 5), 1447S–1454S.
Rokicki, W., Strzalkowski, A., Klapcinska, B., Danch, A., & Sobczak, A. (2003). Antioxidant status in newborns and infants suffering from congenital heart defects. Wiadomosci Lekarskie, 56, 337–340.
Hobbs, C. A., Cleves, M. A., Zhao, W., Melnyk, S., & James, S. J. (2005). Congenital heart defects and maternal biomarkers of oxidative stress. American Journal of Clinical Nutrition, 82, 598–604.
Merialdi, M., Caulfield, L. E., Zavaleta, N., Figueroa, A., Costigan, K. A., Dominici, F., et al. (2004). Randomized controlled trial of prenatal zinc supplementation and fetal bone growth. American Journal of Clinical Nutrition, 79, 826–830.
Duzguner, V., & Kaya, S. (2007). Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxan-induced diabetic rabbits. Free Radical Biology and Medicine, 42, 1481–1486.
King, J. C. (2000). Determinants of maternal zinc status during pregnancy. American Journal of Clinical Nutrition, 71(Suppl. 1), 1334S–1343S.
Song, Y., Wang, J., Li, X. K., & Cai, L. (2005). Zinc and the diabetic heart. BioMetals, 18, 325–332.
Thomas, M., Vidal, A., Bhattacharya, S. K., Ahokas, R. A., Sun, Y., Gerling, I. C., et al. (2007). Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. American Journal of Physiology. Heart and Circulatory Physiology, 293, H2361–H2366.
Xu, L. J., Jin, L., Pan, H., Zhang, A. Z., Wei, G., Li, P. P., et al. (2006). Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacologica Sinica, 27, 1333–1339.
Williams, A. S., Issa, R., Leung, S. Y., Nath, P., Ferguson, G. D., Bennett, B. L., et al. (2007). Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125. Journal of Pharmacology and Experimental Therapeutics, 322, 351–359.
Galdieri, L. C., Arrieta, S. R., Silva, C. M., Pedra, C. A., & D’Almeida, V. (2007). Homocysteine concentrations and molecular analysis in patients with congenital heart defects. Archives of Medical Research, 38, 212–218.
Huhta, J. C., & Hernandez, R. J. A. (2005). Homocysteine, folate, and congenital heart defects. Fetal and Pediatric Pathology, 24, 71–79.
Piao, F., Yokoyama, K., Ma, N., & Yamauchi, T. (2003). Subacute toxic effects of zinc on various tissues and organs of rats. Toxicology Letters, 145, 28–35.